Mezavant

Mesalazine, the active ingredient in Mezavant, is a 5‑aminosalicylic acid (5‑ASA) derivative presented as a delayed‑release tablet for oral use. It is indicated for the treatment of ulcerative colitis in adult patients, helping to reduce colonic inflammation and maintain remission.

GNH USA supplies Mezavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide across multiple continents. The company adheres to stringent quality standards and provides regulatory support for import and distribution. Clients benefit from reliable logistics, batch traceability, and on‑time delivery.

Mezavant (mesalazine) is employed to manage inflammatory conditions of the colon, chiefly ulcerative colitis.

- Ulcerative colitis (induction): reduces active inflammation and induces remission in mild to moderate disease. - Ulcerative colitis (maintenance): helps maintain remission and prevent relapse over long‑term therapy. - Ulcerative proctitis: treats inflammation confined to the rectum, improving bowel habits and reducing bleeding. - Mild to moderate colonic inflammation: alleviates symptoms such as abdominal pain, urgency, and diarrhea.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Nausea: occasional feeling of stomach upset. - Abdominal pain: mild cramping or discomfort. - Headache: transient head pain. - Flatulence: increased intestinal gas. - Rash: mild skin irritation. - Altered taste: temporary change in flavor perception.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas requiring medical attention. - Severe allergic reaction: symptoms such as swelling, hives, or difficulty breathing. - Interstitial nephritis: kidney inflammation that may impair function. - Hepatotoxicity: liver enzyme elevations indicating possible liver injury. - Myocarditis: inflammation of heart muscle, a rare but serious condition. - Blood dyscrasias: abnormal blood counts including anemia or leukopenia.

Before initiating therapy, consider the following precautions.

- Renal function monitoring: assess kidney function periodically, especially in patients with pre‑existing renal disease. - Hepatic function monitoring: check liver enzymes regularly to detect potential hepatotoxicity. - Disease severity assessment: ensure appropriate use in mild to moderate ulcerative colitis. - Hypersensitivity: avoid in patients with known allergy to mesalazine or related compounds. - Concomitant NSAIDs: use with caution as combined therapy may increase risk of renal impairment. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Mesalazine may interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: may reduce mesalazine absorption and effectiveness. - NSAIDs: combined use can increase risk of renal impairment. - Warfarin: may enhance anticoagulant effect and raise bleeding risk.

Moderate Interactions (Monitor Closely): - Diuretics: monitor renal function and electrolytes. - ACE inhibitors: watch for additive effects on kidney function. - Lithium: monitor serum lithium levels for potential toxicity.